<DOC>
	<DOC>NCT02504554</DOC>
	<brief_summary>This is an open-label clinical trial to investigate a combination therapy for treating gastrointestinal problems in children with autism spectrum disorders. The combination therapy includes beneficial bacteria.</brief_summary>
	<brief_title>Beneficial Bacteria Treatment</brief_title>
	<detailed_description>This is an open-label clinical trial to evaluate the safety, tolerability, and feasibility of a combination therapy to treat gastrointestinal problems in children with autism spectrum disorders. It involves a combination therapy including beneficial bacteria.</detailed_description>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>1. Children ages 717 years 2. Diagnosis of autism per Autism Diagnostic InterviewRevised (ADIR) 3. Moderate or Severe GI problems ( on the GSRS, a single score of 4 (severe) on any item, or a score of 3 (moderate) on two items, or a score of 2 (mild) or more on any 4 items 4. No changes in medications, supplements, diet, therapies, or education in last 3 months, and no intention to change them during clinical trial 5. General good physical health aside from gastrointestinal problems 6. Cognitive Ability to Provide Informed Assent 1. Antibiotics in last 6 months 2. Probiotics in last 3 months 3. Singlegene disorder (Fragile X, etc.) 4. Major brain malformation 5. Tube feeding 6. Severe gastrointestinal problems that require immediate treatment (lifethreatening) 7. Ulcerative Colitis, Crohn's Disease, diagnosed Celiac Disease, Eosinophilic Gastroenteritis, or similar conditions 8. Severely underweight/malnourished 9. Recent or scheduled surgeries 10. Current participation in other clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>children</keyword>
</DOC>